Gene · 28402
Papers3,091
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
301 to 320 of 3,091
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The role of CD180 in hematological malignancies and inflammatory disorders. | Mol Med | 2023 | 37460961 | PubTator, text mining | PubMed |
| [Sex-specific differences of special tumor diseases]. | Inn Med (Heidelb) | 2023 | 37458764 | PubTator, text mining | PubMed |
| Membranous nephropathy in chronic lymphocytic leukemia responsive to ibrutinib: A case report. | Leuk Res Rep | 2023 | 37457553 | PubTator, text mining | PubMed |
| Identification of B-cell-related HSPG2 and CDSN as susceptibility loci for Kawasaki disease. | Hum Immunol | 2023 | 37453912 | PubTator, text mining | PubMed |
| Evolution in the frontline treatment of patients with chronic lymphocytic leukemia: experience from one European center. | Leuk Lymphoma | 2023 | 37452739 | PubTator, text mining | PubMed |
| Assessment of ibrutinib scheduling on leukocyte, lymph node size and blood pressure dynamics in chronic lymphocytic leukemia through pharmacokinetic-pharmacodynamic models. | CPT Pharmacometrics Syst Pharmacol | 2023 | 37452622 | PubTator, text mining | PubMed |
| Platelet-derived microparticles provoke chronic lymphocytic leukemia malignancy through metabolic reprogramming. | Front Immunol | 2023 | 37441073 | PubTator, text mining | PubMed |
| Some structural features of the peptide profile of myelin basic protein-hydrolyzing antibodies in schizophrenic patients. | PeerJ | 2023 | 37431466 | PubTator, text mining | PubMed |
| Targeting conditioned media dependencies and FLT-3 in chronic lymphocytic leukemia. | Blood Adv | 2023 | 37428863 | PubTator, text mining | PubMed |
| The inhibitory receptor Siglec-G controls the severity of chronic lymphocytic leukemia. | EMBO Rep | 2023 | 37424400 | PubTator, text mining | PubMed |
| Separate Gut Plasma Cell Populations Produce Auto-Antibodies against Transglutaminase 2 and Transglutaminase 3 in Dermatitis Herpetiformis. | Adv Sci (Weinh) | 2023 | 37424036 | PubTator, text mining | PubMed |
| Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia. | J Hematol Oncol | 2023 | 37422670 | PubTator, text mining | PubMed |
Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma. | Invest New Drugs | 2023 | 37420136 | PubTator, text mining | PubMed |
| Significance of PPARA as a Treatment Target for Chronic Lymphocytic Leukemia. | PPAR Res | 2023 | 37404899 | PubTator, text mining | PubMed |
| Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia. | Blood Cancer J | 2023 | 37400508 | PubTator, text mining | PubMed |
| Clinical efficacy and tolerability of venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia-a real-world analysis of the Polish Adult Leukemia Study Group. | Ann Hematol | 2023 | 37392368 | PubTator, text mining | PubMed |
| The landscape of somatic mutations in lymphoblastoid cell lines. | Cell Genom | 2023 | 37388907 | PubTator, text mining | PubMed |
| Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia: A prospective cohort study. | PLoS Med | 2023 | 37384638 | PubTator, text mining | PubMed |
| Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma. | Blood Adv | 2023 | 37379264 | PubTator, text mining | PubMed |
| A Peculiar CLL Case with Complex Chromosome 6 Rearrangements and Refinement of All Breakpoints at the Gene Level by Genomic Array: A Case Report. | J Clin Med | 2023 | 37373803 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/28402/papers?page=16